Post by comny on Jan 21, 2016 17:57:43 GMT -5
(1) us.gsk.com/en-us/media/press-releases/2015/gsk-to-create-independent-research-institute-with-goal-of-radically-changing-and-improving-medicines-development/
GSK announced today that it is making a substantial investment to launch the Altius Institute for Biomedical Sciences (Altius), an independent, non-profit research institute, in Seattle, Washington. Altius (“higher” in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. ... Expecting Altius to be a catalyst of innovation, GSK has retained first rights to option the Institute’s inventions, and to invest in commercialization of its discoveries via spinout companies.
(2) What does Altius do?
www.forbes.com/sites/luketimmerman/2015/06/16/glaxosmithkline-searching-for-hit-drugs-pours-95m-into-dark-matter-of-the-genome/#2715e4857a0b2216ba1e521c
GSK is hoping that this understanding of gene control will help it find better molecular targets for drugs, and help it select the right compounds, right doses, target tissues, and all kinds of other aspects critical in drug R&D.
“The problem is that the genome only encodes some upstream potentiality, and doesn’t read out what the organism is actually doing,” Stamatoyannopoulos said. “It’s packaged in different ways in different cells…we are reading how the cell is working, and using the genome as a scaffold for all the things it does.” Looking at the downstream manifestation of the genome, in cells, he said, “is going to be much more relevant to clinical medicine.”
(3) MNKD technosphere nanoparticles fit well for targeting different cell types. www.mannkindtechnologies.com/
"Additionally, the processes for Technosphere inhalation powder formation can be readily adjusted to target desired particle sizes that may be required by specific therapies."
(4). Note in the press release: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=951141
a. milestones of up to $102.25 million hard to imagine a start-up company has such deep pocket unless backed up by a big pharma
b. "We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind. -> please note "enhance" and "portfolio" -> multiple products are there -> does not sound receptor is a start up.
c. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. -> "groundbreaking": GSK Altius's work is truly, see their lots of publications in nature and science (laying the foundations)
(5). The company's name "Receptor" gives some hint: In biochemistry and pharmacology, a receptor is a protein molecule that receives chemical signals from outside the cell. When such chemical signals bind to a receptor, they cause some form of cellular/tissue response, e.g. a change in the electrical activity of the cell.
GSK announced today that it is making a substantial investment to launch the Altius Institute for Biomedical Sciences (Altius), an independent, non-profit research institute, in Seattle, Washington. Altius (“higher” in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. ... Expecting Altius to be a catalyst of innovation, GSK has retained first rights to option the Institute’s inventions, and to invest in commercialization of its discoveries via spinout companies.
(2) What does Altius do?
www.forbes.com/sites/luketimmerman/2015/06/16/glaxosmithkline-searching-for-hit-drugs-pours-95m-into-dark-matter-of-the-genome/#2715e4857a0b2216ba1e521c
GSK is hoping that this understanding of gene control will help it find better molecular targets for drugs, and help it select the right compounds, right doses, target tissues, and all kinds of other aspects critical in drug R&D.
“The problem is that the genome only encodes some upstream potentiality, and doesn’t read out what the organism is actually doing,” Stamatoyannopoulos said. “It’s packaged in different ways in different cells…we are reading how the cell is working, and using the genome as a scaffold for all the things it does.” Looking at the downstream manifestation of the genome, in cells, he said, “is going to be much more relevant to clinical medicine.”
(3) MNKD technosphere nanoparticles fit well for targeting different cell types. www.mannkindtechnologies.com/
"Additionally, the processes for Technosphere inhalation powder formation can be readily adjusted to target desired particle sizes that may be required by specific therapies."
(4). Note in the press release: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=951141
a. milestones of up to $102.25 million hard to imagine a start-up company has such deep pocket unless backed up by a big pharma
b. "We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products," said Matthew Pfeffer, Chief Executive Officer of MannKind. -> please note "enhance" and "portfolio" -> multiple products are there -> does not sound receptor is a start up.
c. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market. -> "groundbreaking": GSK Altius's work is truly, see their lots of publications in nature and science (laying the foundations)
(5). The company's name "Receptor" gives some hint: In biochemistry and pharmacology, a receptor is a protein molecule that receives chemical signals from outside the cell. When such chemical signals bind to a receptor, they cause some form of cellular/tissue response, e.g. a change in the electrical activity of the cell.
